ResMed Awarded Group Purchasing Contract with Premier
- Premier members benefit from ResMed's best-in-class non-invasive ventilators and interfaces - ResMed offerings include Astral™, Lumis™ Tx, Stellar™, AcuCare™ NIV masks and associated accessories - Three-year contract begins July 1, 2016
Get Alerts RMD Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 0.8%
Revenue Growth %: +4.8%
Join SI Premium – FREE
SAN DIEGO, June 28, 2016 /PRNewswire/ -- ResMed (NYSE: RMD), the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today announced it has been awarded a three-year supplier group purchasing contract with Premier, a leading healthcare improvement company. Premier unites an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers to transform healthcare.
This new contract will enable Premier-member hospitals and providers to offer their patients the latest in non-invasive ventilation (NIV) technology. From patients with diagnosed sleep apnea to COPD patients requiring NIV during an acute exacerbation, ResMed's NIV products will provide Premier hospitals with the innovative tools they need to be effective in their treatment.
"The chance to offer the life-changing benefits of NIV therapy to more patients is very exciting and we're privileged to play a part in that," said Jon Yerbury, vice president of marketing, ResMed Americas. "Partnering with Premier also expands our market and provides us with more feedback from patients and providers to help drive our next innovations and keep pushing the boundaries in the medical technology space."
About ResMed ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
For media: |
For investors: |
Alison Graves |
Agnes Lee |
Director, Corporate Communications |
Senior Director, Investor Relations |
O: 858-836-6789 |
O: 858-836-5971 |
Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/resmed-awarded-group-purchasing-contract-with-premier-300291089.html
SOURCE ResMed Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
- Alto-Shaam - Restaurants are losing up to $26,000 to food waste, research reveals
- Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!